Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer Journal of Cancer Research & Clinical Oncology, 03/19/2012

Manzoni M et al. – The authors confirmed the predictive role of an increase in circulating endothelial cell (CEC) in metastatic colorectal cancer (mCRC) patients treated with Bevacizumab–based therapy and showed that modifications in CECs and circulating endothelial cell (CEC) number, their apoptotic fraction (APO–CEC) are independent factors. This underlines the relevance of a simultaneous quantitative and functional evaluation of these biomarkers in view of their possible diagnostic utility.

Read this article on Journal of Cancer Research & Clinical Oncology

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Nursing Jobs
@MDLinx Career Center
View the full listing of nursing jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?